The Cure Brain Cancer Foundation has announced an international collaboration on a new adaptive clinical trial platform called GBM AGILE (an Adaptive, Global, Innovative Learning Environment).
How can I get on this trial?
At this stage it is envisaged that there will be sites in Brisbane, Sydney and Melbourne. No further information on specific sites is available at this stage. Information about the trial, including start dates will be listed on the clinical trial registries early next year.
When will it start recruiting?
The trial is expected to begin enrolling patients in mid-2016.
Will I be eligible?
The protocol is currently still in development so eligibility criteria are yet to be finalised. We can confirm that this trial will only be enrolling GBM patients.
Will children be eligible to go on the trial?
The protocol is still being developed. The lower age limit will be lower than 18 years but we do not know how much lower at this stage.
What treatments will be trialed?
The agents that will be assessed through the trial have not yet been determined. They may include immunotherapies, targeted agents and chemotherapies that are identified as promising by the ‘Agent Selection’ sub-committee.
Is this a COGNO study?
COGNO investigators have been working within the AGILE team and have been involved in the design and other aspects of the initiative. However, the exact operational framework and trial sponsorship in Australia are yet to be determined.
How can I find out more information?
Go to curebraincancer.org.au/gbmagileFAQ Please note that the trial is still the development phase.
